Source: BIOSPACE

OncoFusion Therapeutics: Medivation, Inc. Enters Into License Agreement With OncoFusion For Compounds Targeting Bromodomain Proteins

/www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup" ALT"free biotech news">/enewsletters.biospace.com/images/news/cta-latest-biotech-news.jpg" ALIGN"bottom" USEMAP"#cta-BiotechNews" border"0" alt"Get the latest biotech news where you want it. Sign up for the...

Read full article »
OncoFusion Therapeutics's Competitors | OncoFusion Therapeutics's News | OncoFusion Therapeutics's Financials
Stay up-to-date with the latest news on OncoFusion Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
25-100
Shaomeng Wang's photo - Co-Founder of OncoFusion Therapeutics

Co-Founder

Shaomeng Wang

CEO Approval Rating

86/100

Read more
Stay up-to-date with the latest news on OncoFusion Therapeutics